FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385298184> ?p ?o ?g. }

• W4385298184 abstract "Abstract Introduction There is uncertainty regarding how in vitro antibody neutralisation activity translates to the clinical efficacy of sotrovimab against severe acute respiratory syndrome coronavirus 2, although real-world evidence has demonstrated continued effectiveness during both BA.2 and BA.5 predominance. We previously reported descriptive results from the Discover dataset for patients treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or patients at highest risk per National Health Service (NHS) criteria but who were untreated. This study sought to assess the effectiveness of sotrovimab compared with no early coronavirus disease 2019 (COVID-19) treatment in highest-risk patients with COVID-19. Methods Retrospective cohort study using the Discover dataset in North West London. Patients had to be non-hospitalised at index, aged ≥12 years old and meet ≥1 of the NHS highest-risk criteria for receiving early COVID-19 treatment with sotrovimab. The primary objective was to assess the risk of COVID-19-related hospitalisation and/or COVID-19-related death within 28 days of the observed/imputed treatment date between patients treated with sotrovimab and highest-risk patients who received no early COVID-19 treatment. We also performed subgroup analyses for patients aged <65 and ≥65 years, patients with renal dysfunction, and by Omicron subvariant prevalence period (BA.1/2 emergence: 1 December 2021–12 February 2022 [period 1]; BA.2 reaching and at its peak: 13 February–31 May 2022 [period 2]; BA.2 falling and BA.4/5 emergence: 1 June–31 July 2022 [period 3]). Inverse probability of treatment weighting based on propensity scores was used to adjust for measured known and likely confounders between the cohorts. Cox proportional hazards models with stabilised weights were performed to assess hazard ratios (HRs). Results A total of 599 highest-risk patients treated with sotrovimab and 5,191 untreated highest-risk patients were included. Compared with untreated patients, sotrovimab treatment reduced the risk of COVID-19 hospitalisation or death by 50% (HR=0.50; 95% confidence interval [CI] 0.24, 1.06); however, statistical significance was not reached (p=0.07). In addition, sotrovimab reduced the risk of COVID-19 hospitalisation by 57% (HR=0.43; 95% CI 0.18, 1.00) compared with the untreated group, although also not statistically significant (p=0.051). Among patients aged ≥65 years and patients with renal disease, sotrovimab treatment was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR=0.11; 95% CI 0.02, 0.82; p=0.03) and 82% (HR=0.18; 95% CI 0.05, 0.62; p=0.007), respectively. In period 1, sotrovimab treatment was associated with a 75% lower risk of COVID-19 hospitalisation or death compared with the untreated group (HR=0.25; 95% CI 0.07, 0.89; p=0.032). In periods 2 and 3, HRs of COVID-19 hospitalisation or death were 0.53 (95% CI 0.14, 2.00; p=0.35) and 0.78 (95% CI 0.23, 2.69; p=0.69), respectively, for the sotrovimab versus untreated groups, but differences were not statistically significant. Conclusions Sotrovimab treatment was associated with a significant reduction in risk of COVID-19 hospitalisation in patients aged ≥65 years and those with renal disease compared with the untreated cohort. For the overall cohort, the risk of hospitalisation following sotrovimab treatment was also lower compared with the untreated group; however, this did not achieve statistical significance (p=0.051). The risk of hospitalisation and/or death was lower for the sotrovimab-treated cohort across all time periods but did not reach significance for periods 2 and 3." @default.
• W4385298184 created "2023-07-28" @default.
• W4385298184 creator A5001979421 @default.
• W4385298184 creator A5009106593 @default.
• W4385298184 creator A5016416097 @default.
• W4385298184 creator A5019238422 @default.
• W4385298184 creator A5020096923 @default.
• W4385298184 creator A5023232986 @default.
• W4385298184 creator A5031094293 @default.
• W4385298184 creator A5032942541 @default.
• W4385298184 creator A5042019250 @default.
• W4385298184 creator A5042182538 @default.
• W4385298184 creator A5053101231 @default.
• W4385298184 creator A5061084587 @default.
• W4385298184 creator A5082629342 @default.
• W4385298184 creator A5082809410 @default.
• W4385298184 date "2023-07-27" @default.
• W4385298184 modified "2023-09-23" @default.
• W4385298184 title "Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk patients with COVID-19 in North West London: a retrospective cohort study using the Discover dataset" @default.
• W4385298184 cites W2056108924 @default.
• W4385298184 cites W2159515958 @default.
• W4385298184 cites W2785308733 @default.
• W4385298184 cites W3017365620 @default.
• W4385298184 cites W3025744748 @default.
• W4385298184 cites W3135758766 @default.
• W4385298184 cites W4220848096 @default.
• W4385298184 cites W4293063227 @default.
• W4385298184 cites W4306902076 @default.
• W4385298184 cites W4307523553 @default.
• W4385298184 cites W4310368283 @default.
• W4385298184 cites W4315620421 @default.
• W4385298184 cites W4317721984 @default.
• W4385298184 cites W4319937261 @default.
• W4385298184 cites W4323821531 @default.
• W4385298184 doi "https://doi.org/10.1101/2023.07.26.23293188" @default.
• W4385298184 hasPublicationYear "2023" @default.
• W4385298184 type Work @default.
• W4385298184 citedByCount "0" @default.
• W4385298184 crossrefType "posted-content" @default.
• W4385298184 hasAuthorship W4385298184A5001979421 @default.
• W4385298184 hasAuthorship W4385298184A5009106593 @default.
• W4385298184 hasAuthorship W4385298184A5016416097 @default.
• W4385298184 hasAuthorship W4385298184A5019238422 @default.
• W4385298184 hasAuthorship W4385298184A5020096923 @default.
• W4385298184 hasAuthorship W4385298184A5023232986 @default.
• W4385298184 hasAuthorship W4385298184A5031094293 @default.
• W4385298184 hasAuthorship W4385298184A5032942541 @default.
• W4385298184 hasAuthorship W4385298184A5042019250 @default.
• W4385298184 hasAuthorship W4385298184A5042182538 @default.
• W4385298184 hasAuthorship W4385298184A5053101231 @default.
• W4385298184 hasAuthorship W4385298184A5061084587 @default.
• W4385298184 hasAuthorship W4385298184A5082629342 @default.
• W4385298184 hasAuthorship W4385298184A5082809410 @default.
• W4385298184 hasBestOaLocation W43852981841 @default.
• W4385298184 hasConcept C126322002 @default.
• W4385298184 hasConcept C167135981 @default.
• W4385298184 hasConcept C187212893 @default.
• W4385298184 hasConcept C2779134260 @default.
• W4385298184 hasConcept C3008058167 @default.
• W4385298184 hasConcept C524204448 @default.
• W4385298184 hasConcept C71924100 @default.
• W4385298184 hasConcept C72563966 @default.
• W4385298184 hasConcept C89623803 @default.
• W4385298184 hasConceptScore W4385298184C126322002 @default.
• W4385298184 hasConceptScore W4385298184C167135981 @default.
• W4385298184 hasConceptScore W4385298184C187212893 @default.
• W4385298184 hasConceptScore W4385298184C2779134260 @default.
• W4385298184 hasConceptScore W4385298184C3008058167 @default.
• W4385298184 hasConceptScore W4385298184C524204448 @default.
• W4385298184 hasConceptScore W4385298184C71924100 @default.
• W4385298184 hasConceptScore W4385298184C72563966 @default.
• W4385298184 hasConceptScore W4385298184C89623803 @default.
• W4385298184 hasLocation W43852981841 @default.
• W4385298184 hasOpenAccess W4385298184 @default.
• W4385298184 hasPrimaryLocation W43852981841 @default.
• W4385298184 hasRelatedWork W2603773853 @default.
• W4385298184 hasRelatedWork W3103289217 @default.
• W4385298184 hasRelatedWork W3106370311 @default.
• W4385298184 hasRelatedWork W3119540162 @default.
• W4385298184 hasRelatedWork W3152606407 @default.
• W4385298184 hasRelatedWork W3152916563 @default.
• W4385298184 hasRelatedWork W4313474620 @default.
• W4385298184 hasRelatedWork W4327956415 @default.
• W4385298184 hasRelatedWork W4381432928 @default.
• W4385298184 hasRelatedWork W4381942459 @default.
• W4385298184 isParatext "false" @default.
• W4385298184 isRetracted "false" @default.
• W4385298184 workType "article" @default.